These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
171 related articles for article (PubMed ID: 21565498)
1. Discovery of selective and orally available spiro-3-piperidyl ATP-competitive MK2 inhibitors. Kaptein A; Oubrie A; de Zwart E; Hoogenboom N; de Wit J; van de Kar B; van Hoek M; Vogel G; de Kimpe V; Schultz-Fademrecht C; Borsboom J; van Zeeland M; Versteegh J; Kazemier B; de Roos J; Wijnands F; Dulos J; Jaeger M; Leandro-Garcia P; Barf T Bioorg Med Chem Lett; 2011 Jun; 21(12):3823-7. PubMed ID: 21565498 [TBL] [Abstract][Full Text] [Related]
2. Structure-based lead identification of ATP-competitive MK2 inhibitors. Barf T; Kaptein A; de Wilde S; van der Heijden R; van Someren R; Demont D; Schultz-Fademrecht C; Versteegh J; van Zeeland M; Seegers N; Kazemier B; van de Kar B; van Hoek M; de Roos J; Klop H; Smeets R; Hofstra C; Hornberg J; Oubrie A Bioorg Med Chem Lett; 2011 Jun; 21(12):3818-22. PubMed ID: 21565500 [TBL] [Abstract][Full Text] [Related]
3. In vivo and in vitro SAR of tetracyclic MAPKAP-K2 (MK2) inhibitors. Part II. Revesz L; Schlapbach A; Aichholz R; Dawson J; Feifel R; Hawtin S; Littlewood-Evans A; Koch G; Kroemer M; Möbitz H; Scheufler C; Velcicky J; Huppertz C Bioorg Med Chem Lett; 2010 Aug; 20(15):4719-23. PubMed ID: 20591669 [TBL] [Abstract][Full Text] [Related]
4. 2,4-Diaminopyrimidine MK2 inhibitors. Part I: Observation of an unexpected inhibitor binding mode. Argiriadi MA; Ericsson AM; Harris CM; Banach DL; Borhani DW; Calderwood DJ; Demers MD; Dimauro J; Dixon RW; Hardman J; Kwak S; Li B; Mankovich JA; Marcotte D; Mullen KD; Ni B; Pietras M; Sadhukhan R; Sousa S; Tomlinson MJ; Wang L; Xiang T; Talanian RV Bioorg Med Chem Lett; 2010 Jan; 20(1):330-3. PubMed ID: 19919896 [TBL] [Abstract][Full Text] [Related]
6. Facile synthesis of tetracyclic azepine and oxazocine derivatives and their potential as MAPKAP-K2 (MK2) inhibitors. Rao AU; Xiao D; Huang X; Zhou W; Fossetta J; Lundell D; Tian F; Trivedi P; Aslanian R; Palani A Bioorg Med Chem Lett; 2012 Jan; 22(2):1068-72. PubMed ID: 22182499 [TBL] [Abstract][Full Text] [Related]
7. A three-step protocol for lead optimization: quick identification of key conformational features and functional groups in the SAR studies of non-ATP competitive MK2 (MAPKAPK2) inhibitors. Huang X; Zhu X; Chen X; Zhou W; Xiao D; Degrado S; Aslanian R; Fossetta J; Lundell D; Tian F; Trivedi P; Palani A Bioorg Med Chem Lett; 2012 Jan; 22(1):65-70. PubMed ID: 22169260 [TBL] [Abstract][Full Text] [Related]
8. Structural analysis of an MK2-inhibitor complex: insight into the regulation of the secondary structure of the Gly-rich loop by TEI-I01800. Fujino A; Fukushima K; Namiki N; Kosugi T; Takimoto-Kamimura M Acta Crystallogr D Biol Crystallogr; 2010 Jan; 66(Pt 1):80-7. PubMed ID: 20057052 [TBL] [Abstract][Full Text] [Related]
9. 2,4-Diaminopyrimidine MK2 inhibitors. Part II: Structure-based inhibitor optimization. Harris CM; Ericsson AM; Argiriadi MA; Barberis C; Borhani DW; Burchat A; Calderwood DJ; Cunha GA; Dixon RW; Frank KE; Johnson EF; Kamens J; Kwak S; Li B; Mullen KD; Perron DC; Wang L; Wishart N; Wu X; Zhang X; Zmetra TR; Talanian RV Bioorg Med Chem Lett; 2010 Jan; 20(1):334-7. PubMed ID: 19926477 [TBL] [Abstract][Full Text] [Related]
10. Discovery of a novel series of potent MK2 non-ATP competitive inhibitors using 1,2-substituted azoles as cis-amide isosteres. Xiao D; Zhu X; Sofolarides M; Degrado S; Shao N; Rao A; Chen X; Aslanian R; Fossetta J; Tian F; Trivedi P; Lundell D; Palani A Bioorg Med Chem Lett; 2014 Aug; 24(15):3609-13. PubMed ID: 24913714 [TBL] [Abstract][Full Text] [Related]
11. 4-Substituted-7-azaindoles bearing a ureidobenzofuranone moiety as potent and selective, ATP-competitive inhibitors of the mammalian target of rapamycin (mTOR). Tsou HR; MacEwan G; Birnberg G; Zhang N; Brooijmans N; Toral-Barza L; Hollander I; Ayral-Kaloustian S; Yu K Bioorg Med Chem Lett; 2010 Apr; 20(7):2259-63. PubMed ID: 20188551 [TBL] [Abstract][Full Text] [Related]
12. Conformation constraint of anilides enabling the discovery of tricyclic lactams as potent MK2 non-ATP competitive inhibitors. Xiao D; Palani A; Huang X; Sofolarides M; Zhou W; Chen X; Aslanian R; Guo Z; Fossetta J; Tian F; Trivedi P; Spacciapoli P; Whitehurst CE; Lundell D Bioorg Med Chem Lett; 2013 Jun; 23(11):3262-6. PubMed ID: 23602398 [TBL] [Abstract][Full Text] [Related]
13. Novel ATP competitive MK2 inhibitors with potent biochemical and cell-based activity throughout the series. Oubrie A; Kaptein A; de Zwart E; Hoogenboom N; Goorden R; van de Kar B; van Hoek M; de Kimpe V; van der Heijden R; Borsboom J; Kazemier B; de Roos J; Scheffers M; Lommerse J; Schultz-Fademrecht C; Barf T Bioorg Med Chem Lett; 2012 Jan; 22(1):613-8. PubMed ID: 22119462 [TBL] [Abstract][Full Text] [Related]
14. The discovery of Polo-like kinase 4 inhibitors: design and optimization of spiro[cyclopropane-1,3'[3H]indol]-2'(1'H).ones as orally bioavailable antitumor agents. Sampson PB; Liu Y; Patel NK; Feher M; Forrest B; Li SW; Edwards L; Laufer R; Lang Y; Ban F; Awrey DE; Mao G; Plotnikova O; Leung G; Hodgson R; Mason JM; Wei X; Kiarash R; Green E; Qiu W; Chirgadze NY; Mak TW; Pan G; Pauls HW J Med Chem; 2015 Jan; 58(1):130-46. PubMed ID: 24867403 [TBL] [Abstract][Full Text] [Related]
15. Discovery of novel spiro-piperidine derivatives as highly potent and selective melanin-concentrating hormone 1 receptor antagonists. Suzuki T; Moriya M; Sakamoto T; Suga T; Kishino H; Takahashi H; Ishikawa M; Nagai K; Imai Y; Sekino E; Ito M; Iwaasa H; Ishihara A; Tokita S; Kanatani A; Sato N; Fukami T Bioorg Med Chem Lett; 2009 Jun; 19(11):3072-7. PubMed ID: 19403308 [TBL] [Abstract][Full Text] [Related]
16. 4-Anilino-6-phenyl-quinoline inhibitors of mitogen activated protein kinase-activated protein kinase 2 (MK2). Olsson H; Sjö P; Ersoy O; Kristoffersson A; Larsson J; Nordén B Bioorg Med Chem Lett; 2010 Aug; 20(16):4738-40. PubMed ID: 20643547 [TBL] [Abstract][Full Text] [Related]
17. Discovery of potent, selective, and orally bioavailable 3H-spiro[isobenzofuran-1,4'-piperidine] based melanocortin subtype-4 receptor agonists. Guo L; Ye Z; Liu J; He S; Bakshi RK; Sebhat IK; Dobbelaar PH; Hong Q; Jian T; Dellureficio JP; Tsou NN; Ball RG; Weinberg DH; MacNeil T; Tang R; Tamvakopoulos C; Peng Q; Chen HY; Chen AS; Martin WJ; MacIntyre DE; Strack AM; Fong TM; Wyvratt MJ; Nargund RP Bioorg Med Chem Lett; 2010 Aug; 20(16):4895-900. PubMed ID: 20621473 [TBL] [Abstract][Full Text] [Related]
18. Pyrazolopyrimidines as highly potent and selective, ATP-competitive inhibitors of the mammalian target of rapamycin (mTOR): optimization of the 1-substituent. Curran KJ; Verheijen JC; Kaplan J; Richard DJ; Toral-Barza L; Hollander I; Lucas J; Ayral-Kaloustian S; Yu K; Zask A Bioorg Med Chem Lett; 2010 Feb; 20(4):1440-4. PubMed ID: 20089401 [TBL] [Abstract][Full Text] [Related]
19. 2,5-Diaminopyrimidines and 3,5-disubstituted azapurines as inhibitors of glycogen synthase kinase-3 (GSK-3). Lum C; Kahl J; Kessler L; Kucharski J; Lundström J; Miller S; Nakanishi H; Pei Y; Pryor K; Roberts E; Sebo L; Sullivan R; Urban J; Wang Z Bioorg Med Chem Lett; 2008 Jun; 18(12):3578-81. PubMed ID: 18502127 [TBL] [Abstract][Full Text] [Related]
20. Low-molecular-weight MK2 inhibitors: a tough nut to crack! Schlapbach A; Huppertz C Future Med Chem; 2009 Oct; 1(7):1243-57. PubMed ID: 21426101 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]